Skip to main content
NVDA-0.03%AAPL+0.08%GOOGL+1.77%MSFT-0.17%AMZN-0.01%TSM+1.22%SPCX+2.04%AVGO+0.32%META-0.08%TSLA-0.11%SKHY+0.94%MU-0.03%BRK-B+0.66%LLY-0.65%JPM+0.76%WMT+1.34%AMD+2.49%V+0.88%XOM+0.46%ASMLa+0.28%JNJ-0.29%INTC+2.61%MA+0.68%0700.HK+0.66%1398.HK0.00%ABBV+0.83%BAC+0.21%CSCO+4.37%ORCL-1.74%CVX+0.61%COST+0.26%KO+0.52%CAT+1.69%DELL+11.98%LRCX+0.07%AP2d+1.32%AMAT+0.55%HSBA.L+1.54%0005.HK-0.85%PG+1.61%UNH-2.37%MS+0.81%GE-0.15%3988.HK+1.34%1816.HK+0.46%NFLX+1.83%0857.HK-1.09%HD+1.00%GS+0.92%0939.HK-0.20%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%NZDCAD+0.21%USDTRY+0.17%USDILS+0.16%AUDNZD-0.16%EURAUD+0.12%AUDUSD-0.11%GBPAUD+0.10%CHFJPY+0.10%GBPCAD+0.10%AUDCHF-0.09%NZDJPY+0.08%AUDJPY-0.07%CADJPY-0.06%AUDCAD-0.06%NZDUSD+0.05%EURCAD-0.05%NZDCHF+0.05%EURNZD-0.05%USDCOP-0.04%EURJPY-0.02%EURCHF+0.02%GBPCHF-0.02%EURUSD-0.02%GBPUSD+0.01%USDCAD-0.01%EURGBP+0.01%GBPNZD-0.01%USDJPY+0.01%USDCNH+0.01%USDTHB-0.01%USDCHF+0.01%CADCHF0.00%GBPJPY0.00%USDNOK0.00%EURSEK0.00%GBPSGD0.00%GBPZAR0.00%CHFNOK0.00%EURPLN0.00%PLNJPY0.00%NZDMXN0.00%EURNOK0.00%NZDSGD0.00%EURCZK0.00%SGDJPY0.00%NOKJPY0.00%AUDSGD0.00%USDHKD0.00%USDMXN0.00%EURDKK0.00%USDSEK0.00%USDZAR0.00%EURHKD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%USDDKK0.00%USDPLN0.00%AUDDKK0.00%CHFSGD0.00%CHFSEK0.00%USDSGD0.00%GAGUSD0.00%HG10.00%S10.00%USOIL0.00%W10.00%XAGUSD0.00%XAUUSD0.00%C10.00%XNGUSD0.00%COCOA0.00%COFFEE0.00%COTTON0.00%BTCUSD+0.04%ETHUSD-0.55%USDTUSD-0.01%XRPUSD-0.44%SOLUSD-0.35%TRXUSDT+0.52%ZECUSDT-1.88%DOGEUSD-0.58%XMRUSDT-0.78%LINKUSD-0.53%XLMUSD+0.22%BCHUSDT-0.79%LTCUSD+2.13%UNIUSD-1.37%TONUSD+23.75%HBARUSDT+3.13%SUIUSD-0.61%TAOUSDT+1.49%AAVEUSD+0.89%DOTUSDT-0.29%ICPUSDT+1.68%ONDOUSDT+0.56%WLDUSDT-1.64%ARBUSDT-2.06%ATOMUSDT-0.11%JUPUSDT-4.21%INJUSDT+2.73%STXUSDT+1.31%FETUSDT+2.78%PYTHUSDT+4.42%TIAUSDT+2.31%SEIUSDT+2.45%IMXUSDT+2.30%GRTUSDT+2.48%WIFUSDT+0.89%OPUSDT+1.85%POLUSDT+0.87%IOTAUSDT+1.21%AXSUSDT+2.27%FARTCOINUSDT+0.48%EOSUSDT+0.77%DYDXUSDT+0.24%ORDIUSDT-2.17%GALAUSDT+1.49%NOTUSDT+2.53%RONINUSDT+2.65%NVDA-0.03%AAPL+0.08%GOOGL+1.77%MSFT-0.17%AMZN-0.01%TSM+1.22%SPCX+2.04%AVGO+0.32%META-0.08%TSLA-0.11%SKHY+0.94%MU-0.03%BRK-B+0.66%LLY-0.65%JPM+0.76%WMT+1.34%AMD+2.49%V+0.88%XOM+0.46%ASMLa+0.28%JNJ-0.29%INTC+2.61%MA+0.68%0700.HK+0.66%1398.HK0.00%ABBV+0.83%BAC+0.21%CSCO+4.37%ORCL-1.74%CVX+0.61%COST+0.26%KO+0.52%CAT+1.69%DELL+11.98%LRCX+0.07%AP2d+1.32%AMAT+0.55%HSBA.L+1.54%0005.HK-0.85%PG+1.61%UNH-2.37%MS+0.81%GE-0.15%3988.HK+1.34%1816.HK+0.46%NFLX+1.83%0857.HK-1.09%HD+1.00%GS+0.92%0939.HK-0.20%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%NZDCAD+0.21%USDTRY+0.17%USDILS+0.16%AUDNZD-0.16%EURAUD+0.12%AUDUSD-0.11%GBPAUD+0.10%CHFJPY+0.10%GBPCAD+0.10%AUDCHF-0.09%NZDJPY+0.08%AUDJPY-0.07%CADJPY-0.06%AUDCAD-0.06%NZDUSD+0.05%EURCAD-0.05%NZDCHF+0.05%EURNZD-0.05%USDCOP-0.04%EURJPY-0.02%EURCHF+0.02%GBPCHF-0.02%EURUSD-0.02%GBPUSD+0.01%USDCAD-0.01%EURGBP+0.01%GBPNZD-0.01%USDJPY+0.01%USDCNH+0.01%USDTHB-0.01%USDCHF+0.01%CADCHF0.00%GBPJPY0.00%USDNOK0.00%EURSEK0.00%GBPSGD0.00%GBPZAR0.00%CHFNOK0.00%EURPLN0.00%PLNJPY0.00%NZDMXN0.00%EURNOK0.00%NZDSGD0.00%EURCZK0.00%SGDJPY0.00%NOKJPY0.00%AUDSGD0.00%USDHKD0.00%USDMXN0.00%EURDKK0.00%USDSEK0.00%USDZAR0.00%EURHKD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%USDDKK0.00%USDPLN0.00%AUDDKK0.00%CHFSGD0.00%CHFSEK0.00%USDSGD0.00%GAGUSD0.00%HG10.00%S10.00%USOIL0.00%W10.00%XAGUSD0.00%XAUUSD0.00%C10.00%XNGUSD0.00%COCOA0.00%COFFEE0.00%COTTON0.00%BTCUSD+0.04%ETHUSD-0.55%USDTUSD-0.01%XRPUSD-0.44%SOLUSD-0.35%TRXUSDT+0.52%ZECUSDT-1.88%DOGEUSD-0.58%XMRUSDT-0.78%LINKUSD-0.53%XLMUSD+0.22%BCHUSDT-0.79%LTCUSD+2.13%UNIUSD-1.37%TONUSD+23.75%HBARUSDT+3.13%SUIUSD-0.61%TAOUSDT+1.49%AAVEUSD+0.89%DOTUSDT-0.29%ICPUSDT+1.68%ONDOUSDT+0.56%WLDUSDT-1.64%ARBUSDT-2.06%ATOMUSDT-0.11%JUPUSDT-4.21%INJUSDT+2.73%STXUSDT+1.31%FETUSDT+2.78%PYTHUSDT+4.42%TIAUSDT+2.31%SEIUSDT+2.45%IMXUSDT+2.30%GRTUSDT+2.48%WIFUSDT+0.89%OPUSDT+1.85%POLUSDT+0.87%IOTAUSDT+1.21%AXSUSDT+2.27%FARTCOINUSDT+0.48%EOSUSDT+0.77%DYDXUSDT+0.24%ORDIUSDT-2.17%GALAUSDT+1.49%NOTUSDT+2.53%RONINUSDT+2.65%
EP

Eton Pharmaceuticals, Inc. (ETON)

NASDAQ • Healthcare

$57.08
-$0.8 (-1.4%)
Market closed

Last close at September 11, 2026 at 20:00 UTC

Open$58.99
Day Range$56.45 - $59.98
Avg. Volume (3M)585K
Market Cap$1.5B
P/E Ratio121.4
52 Week Range
$14.27$66.37
Next EarningsIn 53 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$37.5M100%
Gross Profitminus cost of goods$25.4M68%
Operating Incomeminus R&D and overhead$12.7M34%
Net Incomeminus taxes and the rest$11.5M31%

In plain terms: out of every $100 in revenue, Eton Pharmaceuticals, Inc. keeps $31 as net profit.

Fundamentals & Financials

Revenue (TTM)
$105.5M
Net Income (TTM)
$12.6M
EPS (TTM)
$0.47
ROA (TTM)
10.96%
Current Ratio
1.52
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-58.3%Q1 2026$0.05
-50.0%Q2 2026$0.05
+126.6%Q3 2026$0.43
Next

Nov 5

in 53 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +126.6%

Revenue nearly doubled year over year in Eton Pharmaceuticals’ second fiscal quarter of 2026, with sales up 98.6% to about $37.6 million (from roughly $18.9 million a year ago) in results reported August 13, 2026, reflecting continued contribution from its rare-disease commercial portfolio across endocrine, metabolic, and liver-related disorders. Profitability at the gross line was reflected in gross profit of about $25.4 million, putting gross margin at ~68% for the quarter. The company also generated operating cash flow of about $7.3 million. Consensus for the next period calls for EPS of $0.34 on revenue of $42.0 million.

View full earnings history

About Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) develops and commercializes rare-disease medicines as a specialty pharmaceutical company, with $80.0 million in FY2025 revenue. Its marketed portfolio spans endocrine, metabolic, and liver-related disorders, and includes products for severe primary IGF-1 deficiency, adrenal disorders, Wilson disease, phenylketonuria, homocystinuria, and tyrosinemia type 1.

Name
Eton Pharmaceuticals, Inc.
CEO
Sean E. Brynjelsen
Website
www.etonpharma.com
Industry
Healthcare
Year Founded
2017
Employees
44

Today's Snapshot

AI-generated

ETON closed 1.4% below yesterday's close, while its sector was flat. Volume was about two-thirds of its usual level.

Trading Volume

Below 10d avg (488.5K)

323.2K

vs S&P 500 Today

Underperforming Market

-2.31%

Updated: September 11, 2026 at 20:17 UTC

Technical Indicators

4 Buy2 Neutral2 Sell
ETON is rated a buy at 57.08 as longer-term trend metrics and medium-term averages remain constructive while short-term averages pressure price. ADX above 30 signals a reasonably strong trend, and MACD's positive level with a neutral RSI suggests underlying bullishness despite short-term momentum weakness and a negative CCI. The stock sits below several short-term SMAs/EMAs but well above the 50/100/200-day averages, ATR shows elevated volatility, and the classic pivot lies above the market acting as nearby resistance. Technical takeaway: Buy.
All signals
  • EMA (5 indicators)$33.05 - $58.95
    Buy
  • RSI (14)52.55
    Neutral
  • Stochastic %K (14, 3, 3)17.74
    Buy
  • MACD Level (12, 26)2.57
    Neutral

Peers & Related Assets

OMEROmeros Corporation
$18.28-1.7%
FULCFulcrum Therapeutics, Inc.
$3.80.0%
ADCTADC Therapeutics S.A.
$1.07-3.6%
RAPTRAPT Therapeutics, Inc.
LXRXLexicon Pharmaceuticals, Inc.
MNPRMonopar Therapeutics Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.